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Communication through quorum sensing (QS) enables bacterial populations to coordinate their behavior.
Recent work on N-acylhomoserine lactone-mediated QS has revealed that some soil bacteria exploit host-
derived substrates to generate an alternative N-substituted homoserine lactone. New light has also been
shed on themechanism bywhichN-(3-oxo-dodecanoyl)-L-homoserine lactonemodulates host inflammatory
signaling pathways to promote bacterial survival.Introduction
Bacteria display complex social behaviors and formcommunities
of cells coordinating their activities through chemical communi-
cation. Because such cooperative behavior is often dependent
on cell population density, it is usually referred to as ‘‘quorum
sensing’’ (QS). Mechanistically, QS involves the activation of a
receptor by a diffusible signal molecule. Consequently, the con-
centration of QS signal reflects the number of bacterial cells and
the sensing of a threshold level of signal indicates that the popu-
lation is ‘‘quorate’’; that is, ready to make a collective decision
(Fuqua and Greenberg, 2002; Lazdunski et al., 2004; Williams,
2007). AlthoughQSwas originally used to describeN-acylhomo-
serine lactone (AHL)-dependent cell-to-cell communication in
Gram-negative bacteria, QS signal molecules exhibit significant
chemical diversity (Figure 1). Where such molecules are respon-
sible for inducing their own biosynthesis, they are referred to as
‘‘autoinducers.’’ Although no ‘‘universal’’ bacterial QS language
has yet been discovered, the autoinducer-2(AI-2)/LuxS QS
system is shared by bothGram-negative andGram-positive bac-
teria. In addition, many bacteria employ more than one QS signal
molecule from the same or a different chemical class, the activi-
ties of which may be coordinated via interacting QS systems,
each of which incorporates a signal molecule synthase and a
sensor/receptor (Fuqua and Greenberg, 2002; Lazdunski et al.,
2004; Williams et al., 2007).
QS controls secondary metabolism, bioluminescence, protein
secretion, motility, virulence factor production, plasmid transfer,
and biofilm maturation in diverse bacteria (Fuqua and Green-
berg, 2002;Williams, 2007). As a result, QS has attracted consid-
erable industrial interest, particularly as a target for novel
antibacterial agents that attenuate bacterial virulence rather
than growth (Bjarnsholt and Givskov, 2007). Because bacteria
cohabit ecosystems with many other organisms, it is perhaps
not surprising to discover that QS signals can modulate the be-
havior of both bacteria other than the QS signal producer itself
and of higher organisms, in ways advantageous for bacterial sur-
vival (Williams, 2007). Conversely, higher organisms manipulate
QS by producing signal mimics, by modulating QS pathways
through the action of cytokines, by blocking QS through the
deployment of inhibitors, or via the enzymatic inactivation of
QS signals.Chemistry & BiologyTwo recent publications in this rapidly expanding field provide
exciting new insights into the chemical diversity, evolution, and
adaptability of AHL-dependent QS signal transduction pathways
(Schaefer et al., 2008) and their effects on the host immune
response (Kravchenko et al., 2008).
N-Alkanoyl- and N-aroyl-Homoserine
Lactone-Dependent QS
AHL-mediatedQSappears to be employed exclusively byGram-
negative bacteria, including beneficial and pathogenic species,
because no AHL-producing Gram-positive bacteria have yet
been identified (Williams, 2007; Williams et al., 2007). Most AHL
producers synthesize multiple AHLs that are characterized by
a homoserine lactone ring, unsubstituted in the b and g positions,
which is N-acylated with an acyl chain incorporating variable
saturation levels and oxidation states. AHLs are exemplified by
compounds with an acyl chain of 4–18 carbons that belong to
either the N-acyl, N-(3-oxoacyl), or N-(3-hydroxyacyl) classes
(Figure 1; Chhabra et al., 2005). AHLs with one or two double
bonds in an acyl chain have also been described. The stereo-
chemistry at the a-center of the homoserine lactone (HSL) ring is
L, and the corresponding D-isomers are, in common with ring-
open compounds, inactive (Chhabra et al., 2005). Consequently,
it is the acyl chain moiety that confers QS signal specificity.
AHL biosynthesis mostly depends on LuxI family proteins that
use S-adenosylmethionine (SAM) and an acyl carrier protein
(ACP) charged with the appropriate fatty acid as sources of the
homoserine lactone (HSL) and acyl chain, respectively (More´
et al., 1996; Fuqua and Greenberg, 2002; Figure 2). Although
one or two compounds usually predominate, most LuxI homo-
logs produce a range of AHLs, indicating that they exhibit
some flexibility and can accept a number of different acyl-ACP
donors (Ortori et al., 2007). In LuxI-driven AHL biosynthesis,
two separate chemical events occur. The irst is the transfer of
the acyl group from the ACP to the amino group of SAM, followed
by lactonization and the release of the AHL and methylthioade-
nosine (Figure 2A). In this reaction mechanism, SAM acts as a
homoserine rather than as a methyl donor (More´ et al., 1996;
Fuqua and Greenberg, 2002). Structural studies of EsaI and
LasI (which produce predominantly N-[3-oxohexanoyl]- L -ho-
moserine lactone and N-[3-oxododecanoyl]- L -homoserine15, November 24, 2008 ª2008 Elsevier Ltd All rights reserved 1141
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substrate-binding pocket for SAM and a common binding site
for the acyl-ACP phosphopantetheine group, which constitutes
a tunnel passing through the enzyme in LasI. This is occluded
in EsaI, a finding that provides a partial explanation for the acyl
chain specificities of the two enzymes (Watson et al., 2002;
Gould et al., 2004).
Once produced, AHLs diffuse across the cell envelope and
subsequently accumulate within the extracellular environment
until a feedback concentration sufficient to activate a target
LuxR family protein hasbeenachieved.AHLsbind to andactivate
LuxRproteins directly such that the LuxR/AHLcomplex activates
or represses one or more target genes that often include the AHL
synthase gene, thus establishing a positive autoinduction circuit
in which the AHL signal also controls its own biosynthesis
(Williams, 2007).
In the pregenomics age, screening for AHLs was often under-
taken using biosensors that typically contained a luxR homolog
plus a target QS-dependent promoter fused to a reporter gene
such as lacZ or lux and maintained in Escherichia coli (a non-
AHL producer) (Swift et al., 1993). By introducing a chromosomal
gene bank into such biosensors and examining clones for DNA
fragments that activated the reporter, novel luxI homologs could
be identified (Swift et al., 1993). New luxI and luxR homologs are
now more likely to be identified via genome-sequencing pro-
jects. Indeed Schaefer et al. (2008) noted the presence of a chro-
mosomal luxIR pair (rpaIR) in the genome of the photosynthetic
bacteriumRhodopseudomonas palustris. This soil bacterium de-
grades a variety of aromatic compounds including p-coumarate
(i.e., p-hydroxycinnamate), a major constituent of the lignin
polymers abundant in plant cell walls. Growth of R. palustris on
p-coumarate as a sole carbon source resulted in the upregula-
Figure 1. Structures of Some Bacterial QS Signal Molecules1142 Chemistry & Biology 15, November 24, 2008 ª2008 Elsevier Ltion of rpaI, implying a link between QS and p-coumarate degra-
dation. However, no activity was observed in AHL-biosensor
assays, implying the presence of a novel class of compounds.
Because rpaI expression was enhanced by growth on p-couma-
rate, the authors fused the rpaI promoter to lacZ and screened
culture supernatants for activating compounds. Only extracts
prepared fromR. palustris grown in the presence of p-coumarate
efficiently activated rpaI::lacZ, whereas bacteria cultured with
other related aromatic compounds such as m-coumarate or
cinnamate exhibited weak activity and AHLs were inactive.
Spectroscopic analysis of the active compound purified from
culture supernatants was consistent with N-(p-coumaroyl)-
L-HSL (pC-HSL) (Figure 1). The function of RpaI as an aroyl-HSL
(the correct nomenclature for this acyl moiety is ‘‘aroyl’’ rather
than ‘‘aryl’’) synthase was initially established by showing that
deletion of rpaI rendered R. palustris unable to synthesize pC-
HSL whereas the expression of rpaI in E. coli or Pseudomonas
aeruginosa resulted in pC-HSL production, but only when exog-
enous p-coumarate was supplied. This is particularly interesting
given that it implies a potential role for the host in facilitating QS
signal synthesis and consequently might impact pathogenic or
beneficial host-bacterial interactions if such systems prove to
be much more widespread than currently appreciated. The puri-
fied RpaI protein was also demonstrated to catalyze pC-HSL
biosynthesis from SAM and p-coumaroyl-CoA (Schaefer et al.,
2008). A charged ACP is the preferred substrate for most LuxI-
type proteins, but CoA-derivatives can be used less efficiently.
Whereas p-coumaroyl-CoA is formed in crude extracts of
R. palustris, the existence of a p–coumaroyl-ACP has yet to be
confirmed. Because RpaI is a LuxI homolog, it would be interest-
ing to determine the substrate specificity of this synthase and
whether it can also catalyze in vitro the formation of AHLs from
SAM and the appropriately fatty acid charged ACPs or CoAs
(Figure 2B).
Given that RpaR is a repressor of rpaI expression and is dere-
pressed on exposure to pC-HSL, it is clear that the RpaIR system
constitutes a novel QS circuit that depends on an exogenous
substrate produced by a different organism. The contribution of
pC-HSL-dependent QS to the lifestyle of R. palustris has not
been fully elucidated, although a microarray analysis following
growth on p-coumarate identified 17 significantly upregulated
genes including rpaI itself and several putative chemotaxis genes
(Schaefer et al., 2008). This could imply a role for RpaIR QS in di-
recting this soil bacterium toward plant roots. Although theRpaIR
regulon appears to be much more limited than the QS regulon of
bacteria such asP. aeruginosa, thismay be a consequence of the
growth conditions employed. Furthermore, pC-HSL-dependent
QS may not be unique to R. palustris because the compound
was detected in spent supernatants from two other environmen-
tal bacterial species (Bradyrhizobium and Silicibacter) whose
genomes contain luxI homologs. Whether these bacteria only
make small amounts or whether p-coumarate is only related to
the natural substrate remains to be determined.
Despite the large number of LuxI protein sequences available,
these often exhibit as little as 30% homology. Phylogenetic
analysis shows that the majority of these proteins cluster within
the same family rather than by the AHL produced. Sequence
comparisons coupled with site-specific mutagenesis revealed
the presence of 10 conserved amino acid residues within thetd All rights reserved
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2002). RpaI possesses nine of these and would have been ex-
pected to synthesize an AHL. Given that RpaI instead synthe-
sizes an aroyl-HSL, these data raise some interesting questions
about the evolution of both RpaI and RpaR given that the latter,
as the cognate receptor, had to coevolve to respond to pC-HSL.
Interestingly, the specificity of LuxR proteins can be modified by
directed or forced evolution to generate proteins with either
relaxed or altered AHL recognition (Collins et al., 2006). Similar
approaches have been taken with LuxI proteins (Brader et al.,
2005), indicating that both LuxR and LuxI homologs are evolu-
tionarily pliable and suggesting that many more N-acyl and
N-aroyl-HSL variants await discovery.
Interestingly, N-(cinnamoyl)- L-HSL, a des-hydroxy analog of
pC-HSL, has previously been synthesized by Geske et al.
(2008), as have other N-acyl, N-sulfonyl, N-aroyl, and N-alka-
noyl-HSLs. Structure-activity relationship (SAR) studies with
these analogs were determined by screening their activity as
agonists or antagonists against three LuxR proteins (TraR,
Figure 2. Biosynthesis of 3-oxo-C6-HSL
and pC-HSL
(A) Biosynthesis of N-(3-oxohexanoyl)homoserine
lactone (3-oxo-C6-HSL) via the charged acyl
carrier protein and either LuxI or RpaI.
(B) Biosynthesis of pC-HSL via the charged acyl
carrier protein and either LuxI or RpaI.
LasR and LuxR). AHLs with acyl groups
containing aromatic functionality with
electron withdrawing groups such as
N-(p-cinnamoyl)- L-HSL generally acted
as antagonists. Conversely, derivatives
with electron-donating substituents
such as hydroxyl on the aromatic ring
were agonists, as was the case with
RpaR and pC-HSL. Clearly there is
a fine balance in RpaR substrate specific-
ity, particularly in terms of electronic and
steric requirements.
QS and the Immune Response
Like R. palustris, P. aeruginosa is an
environmental Gram-negative bacterium
found in soil; however, is also an opportu-
nistic human pathogen. P. aeruginosa
employs both AHLs (primarily 3-oxo-
C12-HSL and N-butanoylhomoserine
lactone [C4-HSL] synthesized via the
LuxI homologs LasI and RhlI, respec-
tively) and 2-alkyl-4-quinolones in a so-
phisticated QS network that controls
secondary metabolite production, biofilm
maturation, and virulence (Williams et al.,
2007). With respect to the latter, the con-
tribution of QS to the pathogenesis of
P. aeruginosa infections has been exten-
sively demonstrated in experimental
animal infection models (Rumbaugh
et al., 2000). Apart from their role as QS signal molecules,
3-oxo-C12-HSL and 2-heptyl-3-hydroxy-4-quinolone (PQS) also
modulate inflammation and immune responses in mammals
(Williams, 2007). Interestingly, the converse also appears to be
true: P. aeruginosa responds to host immune molecules, includ-
ing cytokines, by upregulating QS (Wu et al., 2005). Although
P. aeruginosa is regarded as an opportunistic pathogen in hu-
mans that is responsible for acute infections, it can, once estab-
lished in susceptible individuals suchas thosewith cystic fibrosis,
become chronic and difficult to eradicate with conventional
antibiotic chemotherapy. It has been postulated that QS signal
molecules facilitate chronic P. aeruginosa infections both by reg-
ulating virulence factor expression and bymodifying host inflam-
matory and immune responses (Rumbaugh et al., 2000). It is the
mechanism of this secondary activity that has recently been
clarified for 3-oxo-C12-HSL. AlthoughPQSmodulates inflamma-
tion and immune responses (Hooi et al., 2004), its mechanism of
action remains unclear except that it differs from that of 3-oxo-
C12-HSL. By contrast, there are numerous reports of the effectsChemistry & Biology 15, November 24, 2008 ª2008 Elsevier Ltd All rights reserved 1143
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defining the mammalian intracellular targets of 3-oxo-C12-HSL
have shed significant light on the mechanisms involved.
Many of the effects of 3-oxo-C12-HSL on mammalian cells
occur at concentrations (10–50 mM) that are higher than those
that have been demonstrated in human infections. In planktonic
P. aeruginosa culture supernatants, 3-oxo-C12-HSL is present
at submicromolar levels, although concentrations of up to
600 mM3-oxo-C12-HSL have been reported in biofilms (Charlton
et al., 2000). In sputa and lung tissues from P. aeruginosa-
infected cystic fibrosis patients, 3-oxo-C12-HSL concentrations
are at nanomolar concentrations (Erickson et al., 2002). How-
ever, the presence of lactonases in lung tissue (Ozer et al.,
2005) and the lability of 3-oxo-C12-HSL and other AHLs under
physiological pH and temperature conditions (Yates et al.,
2002) can reduce the detectable levels of AHLs, such that the
actual local concentrations in the tissues might be much higher.
Whether 3-oxo-C12-HSL can diffuse out of the lung and influ-
ence systemic immune responses has yet to be established,
although the lipophilic nature of the molecule suggests that it
could possibly disseminate through the lymphatic system if not
via the bloodstream.
The in vitro effects of 3-oxo-C12-HSL generally fall into two
categories: immunosuppressive or antiinflammatory effects at
concentrations below 10 mM, and proinflammatory or proapop-
totic effects at concentrations of 20 mM and above. The earliest
report of immune modulation by 3-oxo-C12-HSL (Telford et al.,
1998) revealed that concentrations of 3-oxo-C12-HSL below
10 mM could reduce the LPS-induced production of the proin-
flammatory cytokine IL-12 by monocytes in vitro. Such inhibition
of IL-12 production would exert a dampening effect on innate im-
munity, and also, because monocytes can present antigen to
T cells, couldmodulate the outcomes of the adaptive immune re-
sponse. Telford et al. (1998) also showed that 3-oxo-C12-HSL
inhibited mitogen-induced proliferation of lymphocytes, sug-
gesting that it directly inhibited lymphocyte immune responses.
This was confirmed by later reports showing that 3-oxo-C12-
HSL could inhibit the proliferation and function (cytokine produc-
tion) of both mitogen-stimulated (e.g., Chhabra et al., 2003;
Ritchie et al., 2003) and antigen-stimulated (Ritchie et al., 2005)
T lymphocytes, and modulate antibody production by
B lymphocytes (Telford et al., 1998; Ritchie et al., 2003). Overall,
the outcome of this modulation during P. aeruginosa infection
would tend to generate a less effective antibody-mediated,
rather than a more effective cell-mediated, adaptive immune
response to the bacteria, and could thus facilitate persistence.
A SAR study of 3-oxo-C12-HSL indicated that, like QS activity,
immune modulatory activity requires an intact HSL ring, L-con-
figuration at the chiral center, and an acyl chain of 11–13 carbons
(Chhabra et al., 2003).
Other studies have investigated the effects of 3-oxo-C12-HSL
on respiratory epithelial cells and fibroblasts, cell types likely to
be exposed to P. aeruginosa during lung infections, and also
likely to be exposed to the highest in vivo concentrations of
3-oxo-C12-HSL. At concentrations above 20 mM, 3-oxo-C12-
HSL induced production of the neutrophil-attracting chemokine,
CXCL8 (interleukin-8, IL-8), by a range of cell types, including re-
spiratory fibroblast and epithelial cell lines (Smith et al., 2001).
However, Kravchenko et al. (2006) reported that primary respira-1144 Chemistry & Biology 15, November 24, 2008 ª2008 Elsevier Ltory epithelial cells showed no such induction. 3-oxo-C12-HSL is
also chemotactic for neutrophils (Zimmermann et al., 2006). In
contrast to IL-8 production and neutrophil attraction, both of
which would tend to promote inflammation, 3-oxo-C12-HSL
induces apoptosis in both neutrophils and monocytes (Tateda
et al., 2003), an effect confirmed in fibroblasts by Shiner et al.
(2006). This would tend to reduce inflammation by reducing the
number of effective phagocytes and themediators they produce.
However, it has also been argued that together with an increase
in inflammatory mediators leading to host cell damage, the in-
duction of apoptosis in inflammatory cells would favor spread
of invading bacteria and promote persistence of infection
(Rumbaugh et al., 2000).
Although descriptive studies of the varied effects of 3-oxo-
C12-HSL on mammalian cells in vitro have been numerous, it is
only in the last 5 or 6 years that significant advances have been
made in elucidating the mechanisms involved. 3-oxo-C12-HSL
freely enters mammalian cells and retains intracellular activity
(Ritchie et al., 2007; Shiner et al., 2004), but in vivo it is likely
that physiological pH (Yates et al., 2002) and mammalian en-
zymes (Ozer et al., 2005) will substantially reduce extracellular
levels. These findings suggest that the most likely target for
3-oxo-C12-HSL would be an intracellular rather than a cell sur-
face receptor. A number of studies have provided evidence to
support this hypothesis, although only recently has a direct target
for 3-oxo-C12-HSL been identified.
Smith et al. (2002) found that 3-oxo-C12-HSL induced activa-
tion of the proinflammatory signaling componentsCox-2 andNF-
kB in transformed cell lines, although Kravchenko et al. (2006)
suggested that this does not occur in primary cells. 3-oxo-C12-
HSL also inhibited STAT3 activity in a breast cancer cell line (Li
et al., 2004), an interesting finding given that STAT3 is an impor-
tant component of the signal transduction pathway leading to
IL-8 synthesis, and is present in many cell types including im-
mune cells. 3-oxo-C12-HSL also induces phosphorylation of
MAPK p38 and eIFa, both promoters of inflammatory signaling,
but this does not occur through canonical pathogen pattern
recognition receptors such as toll-like receptor 4 (TLR4), the re-
ceptor for LPS, or its downstream components (Kravchenko
et al., 2006). These findings suggested the possibility of a novel
pathogen pattern recognition pathway. However, an interaction
between TLRs and the activity of 3-oxo-C12-HSL was first sug-
gested by a comparison of the results of Tateda et al. (2003),
who showed that 3-oxo-C12-HSL induced inflammatory cyto-
kine production by non-LPS stimulated macrophages, and Tel-
ford et al. (1998), who showed that LPS-stimulated monocyte
IL-12 production was inhibited. These data indicated that the ef-
fects of 3-oxo-C12-HSLonmammalian cellsmight bemodulated
by the presence of other bacterial products, such as LPS, that
signal through TLRs. Another indication of the complexity of the
effects of 3-oxo-C12-HSL on mammalian cells was suggested
by Shiner et al. (2006), who showed that whereas induction of ap-
optosis in fibroblastswasdependent on calciumflux into cells, in-
duction of cytokine production in these cells was not, implying
that at least two different intracellular pathways were affected.
Recently, two seminal papers have shed light on the mecha-
nism of 3-oxo-C12-HSL action in mammalian cells. Kravchenko
et al. (2008) demonstrated that in the absence of LPS, 3-oxo-
C12-HSL alone did not affect NF-kB-mediated signaling, buttd All rights reserved
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(MAPK) p38, which could result in cytokine production. They also
showed that, through its effects onMAPKs, 3-oxo-C12-HSL also
potentiates TNFa-induced poly(adenosine 50-diphosphate-
ribose) (PARP) cleavage, which is a biochemical marker of
apoptosis. However, in LPS-stimulated cells, 3-oxo-C12-HSL
inhibited the LPS-mediated induction of phosphorylation of the
NF-kB associated protein IkB. Because nonphosphorylated
IkB retains NF-kB in the cytoplasm, preventing its translocation
to the nucleus to initiate gene transcription, the effect of 3-oxo-
C12-HSL would be to reduce the intensity of NF-kB signaling
and consequent production of inflammatorymediators, although
some cytokine production could still be induced through 3-oxo-
C12-HSL activation of MAPKs (Kravchenko et al., 2008). The
kinetics of these effects are complex, but the overall effect of
3-oxo-C12-HSL is to attenuate LPS-induced inflammation,
which is likely to contribute to the establishment of persistent
infection by P. aeruginosa. Thus, it is possible that whereas
3-oxo-C12-HSL induces some cytokine production and/or apo-
ptosis in the absence of other bacterial products, this might be
cell-type specific, but in the presence of other bacterial products
that signal via TLRs and NF-kB, 3-oxo-C12-HSL exerts net
antiinflammatory effects.
In their comprehensive study, Kravchenko et al. (2008) did not
identify a direct binding target of 3-oxo-C12-HSL in mammalian
cells. However such a target, the peroxisome proliferator acti-
vated receptors (PPARs) that belong to the nuclear hormone
receptor family has recently been identified (Jahoor et al.,
2008). The PPAR subfamily has broad roles in inflammation
and lipid metabolism and binds a range of endogenous and ex-
ogenous lipids. There are three PPAR isoforms, each of which
has different tissue distributions and ligand specificities, but all
modulate inflammation (Ricote and Glass, 2007). This occurs
through the direct regulation of transcription by the formation
of a ligand-dependent heterodimer with the retinoid X receptor,
which binds to PPAR response elements in a number of genes.
Direct interactions with transcription factors including NFkB
and AP-1 (MAPK pathway) have also been reported, as has
trans-repression involving a range of corepressors and coactiva-
tors (Ricote and Glass, 2007).
Jahoor et al. (2008) used a number of in vitro techniques to
demonstrate that 3-oxo-C12-HSL binds to at least two isoforms
of PPAR (PPARg and PPARb/d) and could modulate the forma-
tion of the PPARg signaling complex with the retinoid X receptor
and its binding to DNA to initiate transcription. Significantly,
a principal mechanism by which PPARs regulate inflammation
is by modulating TLR and NF-kB signaling (De Bosscher et al.,
2006) and inducing phosphorylation of p38 MAPK (Gardner
et al., 2005). Thus, it seems likely that 3-oxo-C12-HSLmodulates
NF-kBsignaling through adirect interactionwith PPARs, and that
the effects of 3-oxo-C12-HSL on PPARs and hence on NF-kB
signaling could in turn be modulated by concomitant signaling
through other pathogen recognition receptors, including TLRs
(Figure 3). Modulation of a subset of TLR pathways by PPARs
has been demonstrated (Ogawa et al., 2005), and an example
of such selective modulation was shown by Gurley et al. (2008)
who reported that in brain macrophages PPARg agonists in-
hibited LPS-induced TNFa production, but augmented LPS-
induced production of macrophage inflammatory protein 2a,Chemistry & Biologya homolog of IL-8. To add to the possibilities for flexibility, 3-
oxo-C12-HSL also differentially modulated signaling though dif-
ferent PPAR isoforms: it appeared to act as an antagonist for
PPARgandanagonist for PPARb/d (Jahoor et al., 2008). Because
PPAR isoform expression is cell-type specific, the outcome of 3-
oxo-C12-HSL interference with mammalian cell signal transduc-
tion pathways might also be to some extent cell-type specific,
and its effects on cellular function are likely to depend on the rel-
ative expression of different PPAR isoforms in different cell types.
The in vitro effects of 3-oxo-C12-HSL on lymphocyte function
can also be explained by modulation of PPAR activity. Some
PPAR agonists have been reported to inhibit cytokine production
and proliferation of lymphocytes (Yang et al., 2000), and if 3-oxo-
C12-HSL modulates MAPK or STAT activity in these cells, this
would inevitably lead to alterations in lymphocyte activation, pro-
liferation and cytokine production. It is also possible that direct
effects of 3-oxo-C12-HSL on dendritic antigen presenting cells
in the lung that subsequently migrate to the lymph nodes and
spleen could result in indirect modulation of T lymphocyte
function, because PPAR agonists have been reported to modu-
late dendritic cell migration (Angeli et al., 2003), maturation
(Gosset et al., 2001) and cytokine production (Faveeuw et al.,
2000). Thus, even if significant extracellular 3-oxo-C12-HSL
does not disseminate from infected lungs, its effects on antigen
presenting cells that migrate out of the lungs after exposure
to antigen could lead to modulation of peripheral immune
responses.
One of the features of P. aeruginosa infection in cystic fibrosis
patients is the striking degree of inflammation. Although a num-
ber of host and bacterial factors have been suggested to contrib-
ute to this, it is also important to note that PPARs are expressed
at lower levels in the cells of cystic fibrosis patients than in cells
of healthy controls (Reynders et al., 2006; Perez et al., 2008), so
any effect of 3-oxo-C12-HSL on PPAR in those cells is likely to
be more potent than in normal cells. Interestingly, a recent study
that used the PPARg agonist rosiglitazone as an antiinflamma-
tory treatment in a mouse model of P. aeruginosa lung infection
showed that the drug was able to attenuate infection-related
inflammation in cystic fibrosis (cftr/) mice but not in normal
Figure 3. Mechanisms Immune Modulation by 3-oxo-C12-HSL
Proposed mechanisms of immune modulation by 3-oxo-C12-HSL. Arrows
indicate positive interactions; lines ending in circles represent negative inter-
actions. Note that reported interactions of PPARs with MAP kinases vary
with the PPAR isoform.15, November 24, 2008 ª2008 Elsevier Ltd All rights reserved 1145
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activity by 3-oxo-C12-HSL produced during P. aeruginosa lung
infection could contribute to inflammation disproportionately in
cystic fibrosis patients compared with other susceptible individ-
uals such as burns patients or the immunocompromised.
In summary, these recent developments in the QS field extend
the repertoire of N-substituted homoserine lactones now known
to be employed as bacterial signal molecules and refine our un-
derstanding of the contribution of such molecules to host-path-
ogen interactions. Paradoxically, 3-oxo-C12-HSL and related
molecules have significant therapeutic potential as antiinflam-
matory or immunosuppressive agents, whereas 3-oxo-C12-
HSL-dependent QS remains an attractive target for novel
antipseudomonal agents that control infection through the
downregulation of bacterial virulence.
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